To hear about similar clinical trials, please enter your email below
Trial Title:
Survivorship After HNC: a Randomized Controlled Trial Evaluating Patient Care and Adherence to Follow-up
NCT ID:
NCT06127784
Condition:
Head and Neck Cancer
Survivorship
Conditions: Official terms:
Head and Neck Neoplasms
Conditions: Keywords:
Motivational Interviewing
Counselling
Survivorship Care Plan
Treatment Adherence
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
A prospective, randomized controlled trial at a single centre with 2 groups of 90 adults.
The intervention group will receive a one-hour treatment summary and survivorship care
plan (TSSP) intervention specifically tailored to the needs of head and neck cancer
patients delivered within a motivational interviewing counselling session with a clinical
nurse specialist. The standard care group will receive standard of care treatment.
Primary purpose:
Supportive Care
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
Motivational interviewing counselling session
Description:
Individually tailored treatment summary and survivorship care plan provided within a
1-hour 1 hour counseling session with a clinical nurse specialist
Arm group label:
MI Counselling
Other name:
MI
Summary:
Treatment summary and survivorship care plans (TSSPs) are poorly studied in Head and Neck
Cancer (HNC) patients, and given the high frequency of unmet needs, this patient
population has potentially the most to benefit from the implementation of TSSPs. A
preliminary feasibility randomized control trial (RCT) at London Regional Cancer Program
(LRCP) of 18 patients with HNC evaluating the implementation of TSSPs, found that
patients assigned to the intervention group had a 15% higher rate of physician
implementation of survivorship care needs compared to the usual care group (40% versus
25%, respectively). Results of the pilot study indicated that successful execution of
TSSPs and counselling sessions for HNC patients is feasible. In follow up to the initial
feasibility trial, the present investigation seeks to execute a large-scale randomized
controlled trial. Three hundred and four patients who were treated at the London Regional
Cancer Program (LRCP) for HNC will be randomly assigned to either usual care or a
survivorship care plan (TSSP) intervention (90 patients in each arm). The intervention
will consist of the delivery of a TSSP and a motivational interviewing counseling session
with a clinical nurse specialist tailored to the needs of this vulnerable cancer
population. The primary objective of the study is to evaluate the delivery of a TSSP
during a one-on-one motivational interviewing counselling session with HNC survivors to
determine whether the intervention results in improved implementation of recommendations
for HNC survivors compared to usual care. Secondary study objectives will evaluate
quality of life and satisfaction with care at 12 months post-intervention between the
usual care and intervention group. Primary care providers of patients assigned to the
intervention group will also be surveyed on the utility of the TSSP.
Detailed description:
This study is a longitudinal randomized controlled trial. Patients will be randomly
assigned to either usual treatment or the intervention (MI counselling session). Data
will be collected at four time points: baseline (3-6 months post-treatment for HNC), and
3-, 6- and 12- months post-baseline visit. 180 patients with curable stage I-IV head and
neck mucosal cancer (HNC) will be recruited to the study (90 per arm).
The intervention will consist of a survivorship care nurse motivational interviewing
counseling session coupled with the provision of individualized TSSPs to patients and
their health care providers.
The primary outcome will be physician implementation of survivorship care recommendations
over the course of 12 months post-intervention assessed by quarterly patient surveys.
Secondary outcomes will include adherence to recommended follow-up schedules, quality of
life using validated measures, patient satisfaction with care, patient feedback on the
utility of the TSSP and counselling session and physician feedback on the utility of the
TSSP.
Criteria for eligibility:
Criteria:
Patient Participants
Inclusion Criteria:
- Age 18 years or older
- Willing to provide informed consent
- Diagnosis of stage I-IVA head and neck mucosal cancer (larynx, hypopharynx, oral
cavity, oropharynx, nasopharynx)
- Last definitive treatment (surgery, chemotherapy, radiotherapy) between 3 and 6
months prior to enrollment
- English speaking, reading and writing
Exclusion Criteria:
- Second concurrent non-cutaneous malignancy
- Metastatic disease
- Clinically apparent cognitive impairment
- Suspected residual disease after treatment completion
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
November 1, 2024
Completion date:
July 1, 2027
Lead sponsor:
Agency:
Western University, Canada
Agency class:
Other
Source:
Western University, Canada
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06127784